A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021
暂无分享,去创建一个
Shaghayegh Haghjooy Javanmard | Christopher J. L. Murray | T. Vos | A. Ferrari | A. Aravkin | A. Flaxman | S. Hay | D. Pigott | B. Duncan | G. Bonsel | C. Abbafati | Z. Al-Aly | A. Carter | N. Fullman | J. Haagsma | Kristopher J. Krohn | R. Lozano | D. Malta | N. Mohammadifard | A. Mokdad | L. Monasta | R. Reiner | D. Santomauro | N. Sarrafzadegan | J. Soriano | C. Wiysonge | G. Ribbers | M. Puhan | J. Aerts | P. Glybochko | E. Castro | A. Gamkrelidze | J. Månsson | Farah Daoud | R. van den Berg-Emons | M. Kereselidze | Erin B Hamilton | M. Hellemons | A. Malinovschi | J. Peñalvo | Jiawei He | I. Larsson | E. Wallin | S. Rubertsson | R. Helbok | O. Ogbuoji | D. Buonsenso | H. Chu | P. Valentini | C. De Rose | R. Frithiof | D. McCulloch | B. Magistro | D. Menges | T. Ballouz | James Collins | Peng Zheng | C. Adolph | J. Albright | B. Bang-Jensen | Suman Chakrabarti | Xiaochen Dai | Samuel B. Ewald | E. Hulland | Alice Lazzar-Atwood | Akiaja Lindstrom | Maja Pašović | G. Reinke | A. Sholokhov | E. Spurlock | V. Rass | Nickolas Reinig | Chelsea Liu | D. Butnaru | A. Svistunov | Hanzhang Xu | M. Heijenbrok-Kal | J. Giles | M. Witzenrath | F. Kurth | W. Jassat | Nikita A. Nekliudov | M. M. Diab | B. J. van de Water | M. El Tantawi | W. Mao | M. Hultström | Charlie Ashbaugh | Kyle E Simpson | Sarah Wulf Hanson | J. Bettger | D. Munblit | A. Ricchiuto | D. Sinatti | A. M. Mantilla Herrera | M. Lipcsey | S. Huijts | C. Bisignano | Gaorui Guo | I. M. Osmanov | F. Steinbeis | Anastasia Shikhaleva | E. Samitova | Monika Helak | O. Blyuss | V. Fomin | M. S. Petersen | N. Nekliudov | G. Harris | R. Walcott | Callan Loflin | D. Hillus | Thomas Zoller | S. Borzakova | Austin Carter | C. Murray | Shuhei Nomura | P. Bobkova | Emil Ekbom | A. Gamirova | L. Mazankova | Mujibur Rahman | E. Spiridonova | Yifan Wu | Joanne O Amlag | Rachel Castellano | Carolyn Dapper | A. Deen | Megan Erickson | A. L. P. Ribeiro | Ally Walker | T. Zoller | Denise J. McCulloch | Kyle E. Simpson | Callan D Loflin | A. P. L. Ribeiro | Z. Al‐Aly | I. Osmanov | M. Diab | Gabrielle M. Harris | J. Collins | A. L. Ribeiro | X. Dai | Antonia Ricchiuto | Bree L Bang-Jensen | Beatrice Magistro | Grace Reinke | Verena Rass | Ewa Wallin | Emma Castro
[1] Reed J. D. Sorensen,et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis , 2022, The Lancet.
[2] Reed J. D. Sorensen,et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.
[3] H. Bundgaard,et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study , 2022, The Lancet Child & Adolescent Health.
[4] A. Slooter,et al. Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19. , 2022, JAMA.
[5] Shaghayegh Haghjooy Javanmard,et al. Isfahan COVID cohort study: Rationale, methodology, and initial results , 2022, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.
[6] I. Tleyjeh,et al. Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up , 2021, PloS one.
[7] Janet Diaz,et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.
[8] Brendan R. Jackson,et al. Long-Term Symptoms Among Adults Tested for SARS-CoV-2 — United States, January 2020–April 2021 , 2021, MMWR. Morbidity and mortality weekly report.
[9] A. Akbari,et al. Long COVID in children and adolescents , 2021, World Journal of Pediatrics.
[10] K. T. Kalleberg,et al. Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study , 2021, PloS one.
[11] G. Ribbers,et al. CO-FLOW: COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system: study protocol of a multicenter prospective cohort study following patients 2 years after hospital discharge , 2021, BMC Health Services Research.
[12] L. Horwitz,et al. Six-Month Outcomes in Patients Hospitalized with Severe COVID-19 , 2021, Journal of General Internal Medicine.
[13] B. D. De Stavola,et al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study) , 2021, BMJ Open.
[14] N. Belfeki,et al. Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France , 2021, Microorganisms.
[15] T. Spector,et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2 , 2021, The Lancet. Child & adolescent health.
[16] A. Galiana,et al. Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study , 2021, Journal of Clinical Immunology.
[17] R. Guner,et al. Post‐COVID syndrome: A single‐center questionnaire study on 1007 participants recovered from COVID‐19 , 2021, Journal of medical virology.
[18] Post-Acute COVID Syndrome, the Aftermath of Mild to Severe COVID-19 in Brazilian Patients , 2021, medRxiv.
[19] M. Isola,et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients , 2021, Clinical Microbiology and Infection.
[20] R. Riera,et al. Frequency, signs and symptoms, and criteria adopted for long COVID‐19: A systematic review , 2021, International journal of clinical practice.
[21] Reed J. D. Sorensen,et al. Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic , 2021, JAMA network open.
[22] D. Stuart,et al. The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom , 2021, medRxiv.
[23] A. Steer,et al. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease , 2021, The Lancet Child & Adolescent Health.
[24] M. A.,et al. Impaired diffusing capacity for carbon monoxide is common in critically ill Covid-19 patients at four months post-discharge , 2021, Respiratory Medicine.
[25] Md. Mujibur Rahman,et al. Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh , 2021, PloS one.
[26] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[27] W. Lim,et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol , 2021, The Lancet Regional Health - Europe.
[28] D. Brodie,et al. Post-acute COVID-19 syndrome , 2021, Nature Medicine.
[29] A. Azman,et al. Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance , 2021, medRxiv.
[30] David A. Drew,et al. Attributes and predictors of long COVID , 2021, Nature Medicine.
[31] 12,et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay , 2021, medRxiv.
[32] Milad Asgari Mehrabadi,et al. COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic , 2021, medRxiv.
[33] J. Barberà,et al. Lung Function Sequelae In Covid-19 Patients 3 Months After Hospital Discharge , 2021, Archivos de Bronconeumología.
[34] Y. Benjamini,et al. Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients , 2021, Clinical Microbiology and Infection.
[35] F. Anastasio,et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life , 2021, European Respiratory Journal.
[36] C. Wolf,et al. Sequelae in Adults at 6 Months After COVID-19 Infection , 2021, JAMA network open.
[37] D. Buonsenso,et al. Preliminary evidence on long COVID in children , 2021, medRxiv.
[38] A. Larsson,et al. Severe acute kidney injury associated with progression of chronic kidney disease after critical COVID-19 , 2021, Critical Care.
[39] Benjamin Bowe,et al. High-dimensional characterization of post-acute sequelae of COVID-19 , 2021, Nature.
[40] S. Villapol,et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.
[41] A. Bellasi,et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation , 2021, Epidemiology and Infection.
[42] M. Andrés,et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study , 2021, Journal of Infection.
[43] Guohui Fan,et al. RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.
[44] E. Price-Haywood,et al. The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study , 2021, Clinical Microbiology and Infection.
[45] C. Gramaglia,et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge , 2021, JAMA network open.
[46] S. Kiechl,et al. Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study , 2020, European journal of neurology.
[47] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[49] N. Wig,et al. Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India. , 2021, Drug discoveries & therapeutics.
[50] A. Komaroff,et al. Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? , 2021, Frontiers in Medicine.
[51] M. Sivan,et al. NICE guideline on long covid , 2020, BMJ.
[52] K. Stavem,et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19 , 2020, European Respiratory Journal.
[53] C. Ryerson,et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations , 2020, Thorax.
[54] N. Lorenzo-Villalba,et al. Ninety days post-hospitalization evaluation of residual COVID-19 symptoms through a phone call check list , 2020, The Pan African medical journal.
[55] P. Weihe,et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[56] V. F. Simões,et al. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão , 2020, Revista de saude publica.
[57] S. Madhi,et al. Long-COVID: An evolving problem with an extensive impact. , 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[58] J. Ludvigsson. Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19 , 2020, Acta paediatrica.
[59] T. Greenhalgh,et al. Developing services for long Covid: lessons from a study of wounded healers , 2020, medRxiv.
[60] V. Chopra,et al. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 , 2020, Annals of Internal Medicine.
[61] P. Bieniasz,et al. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients , 2020, The Journal of Infectious Diseases.
[62] Jeremy S. Brown,et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19 , 2020, Thorax.
[63] E. Bonifacio,et al. A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children , 2020, Med.
[64] H. Krumholz,et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study , 2020, The American Journal of Medicine.
[65] C. Donnelly,et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults , 2020, medRxiv.
[66] N. Washington,et al. Long-term COVID-19 symptoms in a large unselected population , 2020 .
[67] F. Callard,et al. How and why patients made Long Covid , 2020, Social Science & Medicine.
[68] F. Bruyère,et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset , 2020, Clinical Microbiology and Infection.
[69] Eun Sug Park,et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.
[70] B. Fantin,et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19 , 2020, Journal of Infection.
[71] N. Maskell,et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. , 2020, medRxiv.
[72] Manoj Sivan,et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation , 2020, Journal of medical virology.
[73] P. Kirchhof,et al. Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.
[74] M. Devita,et al. Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.
[75] K. Jhaveri,et al. COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings. , 2020, Journal of the American Society of Nephrology : JASN.
[76] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.
[77] H. Krumholz,et al. Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.
[78] C. von Kalle,et al. Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19) , 2020, Infection.
[79] J. Kuhle,et al. Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19 , 2020, Journal of Neurology.
[80] Eric J Topol,et al. Prevalence of Asymptomatic SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.
[81] A. Abdullahi,et al. Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19 , 2020, Physiotherapy theory and practice.
[82] F. Tacke,et al. Studying the pathophysiology of coronavirus disease 2019 - a protocol for the Berlin prospective COVID-19 patient cohort (Pa- COVID-19) , 2020, medRxiv.
[83] W. Brady,et al. Cardiovascular complications in COVID-19 , 2020, The American Journal of Emergency Medicine.
[84] John S. Brownstein,et al. Epidemiological data from the COVID-19 outbreak, real-time case information , 2020, Scientific Data.
[85] E. Dong,et al. An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.
[86] Peng Zheng,et al. Trimmed Constrained Mixed Effects Models: Formulations and Algorithms , 2019, bioRxiv.
[87] A. Komaroff. Advances in Understanding the Pathophysiology of Chronic Fatigue Syndrome. , 2019, JAMA.
[88] T. Vos,et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2016, PLoS medicine.
[89] Emmanouel A. Varvarigos,et al. Survey , 2016, ACM Comput. Surv..
[90] Mirjam Kretzschmar,et al. Disability weights for the Global Burden of Disease 2013 study. , 2015, The Lancet. Global health.
[91] D. Needham,et al. Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders' conference* , 2012, Critical care medicine.
[92] H. Moldofsky,et al. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study , 2011, BMC neurology.
[93] Bernice B Brown,et al. DELPHI PROCESS: A METHODOLOGY USED FOR THE ELICITATION OF OPINIONS OF EXPERTS , 1968 .